Disclosed are nanovectors of formula (I) that can be used simultaneously for the targeting, imaging and treatment, by photodynamic therapy, of cancer cells, and to biodegradable silicon nanoparticles containing a variety of photosensitizing molecules, in particular porphyrins, capable of targeting diseased cells and inducing cell death by excitation in the near-infrared region (>600 nm) in monophotonic and biphotonic modes. In formula (I), (AA) is a porous silicon nanoparticle.

Methods and systems for treatment of hypoxic tumors are provided, including the steps of positioning a delivery device in a bodily cavity adjacent to tumor tissue, delivering an oxygenating agent to the tumor tissue via the delivery device and radiating the tumor tissue with radiation. Methods and systems of treatment of tumors are also provided, including the steps of positioning a delivery device in a bodily cavity adjacent to tumor tissue, delivering a photosensitizing agent to the tumor tissue via the delivery device, and radiating the tumor tissue with light.

Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

Methods for treating liver cancer in a patient are provided. The methods include steps of administering at least one dose of a therapeutically effective amount of a composition comprising indocyanine green (ICG) and applying a PDT light source to the liver of the patient, wherein the PDT light source comprises a transarterial fiber optic coaxial catheter comprising a laser light, a sheet having an array of light-emitting diode (LED) lights, or a micro-injectable LED implant configured for delivery inside the liver, wherein the PDT light source is applied for a time period sufficient to release reactive oxygen species from the photosensitizing agent and induce apoptosis of cancer cells. A PDT system may include a composition comprising ICG and a PDT device comprising at least one light source enabled for application of light to a target tumor.

A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn.sub.2SiO.sub.4:Mn.sup.2+ and (3Ca.sub.3(PO.sub.4).sub.2Ca(F, Cl).sub.2:Sb.sup.3+, Mn.sup.2+) at a ratio (Zn.sub.2SiO.sub.4:Mn.sup.2+):(3Ca.sub.3(PO.sub.4).sub.2Ca(F, Cl).sub.2:Sb.sup.3+, Mn.sup.2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.

The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (ErR.sub.3) that are capable of killing the bladder tumor cells selectivity via .sup.1O.sub.2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon ErR.sub.3 binding with the integrin .sub.v.sub.3 isoform in bladder cancer cells.

The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

Photosensitizer compositions effective against various microbial infections, in addition to methods for making the same, are disclosed. In addition, phototherapy devices and methods for delivering light to tissues to activate photoactive agents are also disclosed. Further, methods for using the phototherapy device in combination with photosensitizer compositions are described.

A method, composition and system respond to ionizing radiation to adjust biological activity. In some approaches the ionizing radiation is X-ray or extreme ultraviolet radiation that produces luminescent responses that induce biologically active responses.